Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat newly diagnosed, relapsed, and refractory multiple myeloma in adults. It works by binding to cancer cells, causing cell death. It is administered as a subcutaneous read more

Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat newly diagnosed, relapsed, and refractory multiple myeloma in adults. It works by binding to cancer cells, causing cell death. It is administered as a subcutaneous injection by a healthcare professional, usually in a clinic or doctor's office.

Common side effects include:
- Respiratory tract infection
- Constipation
- Nausea
- Fatigue
- Fever
- Diarrhea
- Cough
- Insomnia
- Vomiting
- Back pain

Rare but serious side effects include:
- Severe injection reactions
- Low blood cell counts
- Fetal harm

For more details, you can visit the official Darzalex website or the Multiple Myeloma Research Foundation.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Darzalex Faspro (Daratumumab and hyaluronidase-fihj) for Myeloma | MyMyelomaTeam

Darzalex (Daratumumab) for Myeloma | MyMyelomaTeam